ReviewFrontiers in neurology2020
Thalamic Injury and Cognition in Multiple Sclerosis.
Review in Frontiers in neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 60 citations in OpenAlex.
- Dissociating Fatigue and Fatigability in Multiple Sclerosis: The Role of Cognitive Processing Speed.European journal of neurology · 2026Article
- Brain Morphological Alterations in Adults with Spinal Muscular Atrophy Types 2 and 3: A CAT12-Derived Region-Based and Surface-Based Morphometry Study.Journal of clinical medicine · 2026Article
- Thalamic nuclei volumes across psychiatric and neurological disorders: a multi-site magnetic resonance imaging study.Translational psychiatry · 2026Article
- Comparative profiling of neurological and biomarker status in type 1 diabetes and multiple sclerosis: A cross-sectional observational study.Brain, behavior, & immunity - health · 2026Article
- Cognition and fatigue in clinically stable multiple sclerosis: EDSS and MRI metrics outperform serum biomarkers.BMC neurology · 2026Article
- Volumetric MRI Markers of Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis: Cerebellar White Matter Loss, Pallidum Atrophy, and Choroid Plexus Enlargement.Brain sciences · 2026Article
- Progression-related outcomes of teriflunomide in multiple sclerosis clinical trials.Frontiers in neurology · 2026Review
- Microstructure-informed deep learning improves thalamic atrophy segmentation and clinical associations in multiple sclerosis and related neuroimmunological diseases.NeuroImage. Clinical · 2026Article
- Association of decreased thalamic neurotransmitter level with sensorimotor tract damage in patients with relapsing-remitting multiple sclerosis.Quantitative imaging in medicine and surgery · 2025Article
- Article
- Multiple sclerosis and the risk of dementia: a real-world, nationwide cohort study.Frontiers in neurology · 2025Article
- Thalamus anatomy predicts cognitive performance and hippocampal atrophy in aging adults: a UK Biobank study.Brain communications · 2025Article
- Amygdala volume changes as a potential marker of multiple sclerosis progression: links to EDSS scores and PIRA.Frontiers in immunology · 2025Article
- Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease.Neuroradiology · 2025Article
- Cross-sectional and longitudinal evaluation of white matter microstructure damage and cognitive correlations by automated fibre quantification in relapsing-remitting multiple sclerosis patients.Brain imaging and behavior · 2024Article
- Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Vascular Disease Is Associated With Differences in Brain Structure and Lower Cognitive Functioning in Inflammatory Bowel Disease: A Cross-Sectional Study.Inflammatory bowel diseases · 2024Article
- Mapping the Relationship of White Matter Lesions to Depression in Multiple Sclerosis.Biological psychiatry · 2024Article
- Brain control of dual-task walking can be improved in aging and neurological disease.GeroScience · 2024Article
- Causal relationships of grey matter structures in multiple sclerosis and neuromyelitis optica spectrum disorder: insights from Mendelian randomization.Brain communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) produces demyelination and degeneration in both gray and white matter. Both cortical and deep gray matter injury is observed during the course of MS. Among deep gray matter structures, the thalamus has received special attention, as it undergoes volume loss in different MS subtypes and is involved in the earliest form of the disease, radiologically isolated syndrome. The thalamus plays an important role as an information relay center, and involvement of the thalamus in MS has been associated with a variety of clinical manifestations in MS, including fatigue, movement disorders, pain, and cognitive impairment (CI). Similar to thalamic volume loss, CI is seen from the earliest stages of MS and is potentially one of the most debilitating manifestations of the disease. The thalamus, particularly the dorsomedial nucleus as part of the basolateral limbic circuit and anterior thalamic nuclei through connections with the prefrontal cortex, has been shown to be involved in CI. Specifically, several cognitive performance measures such as processing speed and memory correlate with thalamic volume. Thalamic atrophy is one of the most important predictors of CI in MS, and both thalamic volume, diffusion tensor imaging measures, and functional activation correlate with the degree of CI in MS. Although the exact mechanism of thalamic atrophy is not well-understood, it is hypothesized to be secondary to degeneration following white matter injury resulting in secondary neurodegeneration and neuronal loss. The thalamus may represent an ideal biomarker for studies aiming to test neuroprotective or restorative therapies aimed at cognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.